GlycoMimetics, Inc. announced today that the first healthy volunteer has been dosed in a Phase 1 clinical study designed to evaluate the safety, tolerability and pharmacokinetics of GMI-1271 , a novel and proprietary E-selectin antagonist in the company's pipeline.
http://ift.tt/1qhzM8J
http://ift.tt/1qhzM8J
No comments:
Post a Comment